Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1188-21-2
Molecular formula
C8H15NO3
Molecular weight
173.21 g/mol
Drug class
Acetylated L-leucineneurometabolic therapy for selected inherited neurological disorders
Mechanism of action
The mechanism is not fully established. Acetylated leucine may modulate neuronal energy metabolism, membrane stability and cerebellar network function; no single molecular target is confirmed as the clinical mechanism.
Indications / reported uses
Treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients weighing at least 15 kg under the US AQNEURSA indication
Treatment of ataxia-telangiectasia in adults and paediatric patients weighing at least 15 kg under the US indication where authorised; verify current label wording for disease-specific use
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Levacetylleucine Environmental Risk Assessment (ERA) (the Levacetylleucine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.